Immunotherapy and urothelial carcinoma: An overview and future prospectives

Pierantoni, Francesco; Maruzzo, Marco; Gardi, Mario; Bezzon, Elisabetta; Gardiman, Marina Paola; Porreca, Angelo; Basso, Umberto; Zagonel, Vittorina

doi:10.1016/j.critrevonc.2019.08.005

Cited by 21 publications

(13 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Until recently, the treatment for BC remain limited, including surgery, chemo-radiotherapy, immunotherapy, etc. The limited number of treatments contributed to little progress, with a flat 5-year survival rate [3,4]. Significantly, up to 25% of new diagnosed cases present as muscle-invasive or advanced stage (T2-T4),with a very poor prognosis [5].…”

Section: Introductionmentioning

confidence: 99%

A new m6A methylation-related gene signature for prognostic value in patient with urothelial carcinoma of the bladder

et al. 2021

View full text Add to dashboard Cite

Background: Bladder cancer (BC) is one of the most common malignant urological cancer in the world. Because of its characteristic of easy-recurrence and muscle-invasive, advances in our genetic understanding of bladder cancer should be translated into prognostic indicators. Methods: We investigated 16 m6A RNA methylation regulators from The Cancer Genome Atlas (TCGA) database and The Human Protein Atlas (HPA) database. The expression profile, clinical application as well as prognostic value of these genes in UC were investigated. Moreover, we further explored the correlation between RNA methylation genes and biological functions, pathways and immune status. Results: Five m6A-related genes (HNRNPC, YTHDF2, YTHDF1, HNRNPA2B1, METTL3) upregulated in UC tissues, while three regulators (ZC3H13, METTL16, FTO) downregulated in UC. FTO and YTHDF2 show biomarker potential for the prognosis of UC patients. In addition, these identified genes may related with essential functions and core molecular pathways. Conclusions: Our research shows that two m6A RNA methylation regulators can serve as reliable prognostic biomarkers of UC, which might be exerted as potential targets of therapeutic strategies.

show abstract

Section: Introductionmentioning

confidence: 99%

A new m6A methylation-related gene signature for prognostic value in patient with urothelial carcinoma of the bladder

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Currently, bladder preservation is becoming a hot topic. Immune checkpoint inhibitors have increasingly become a therapeutic option for many solid tumors ( 42 , 43 ). In BC, high expression of anti-programmed cell-death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) have been found to be closely related with advanced and aggressive tumors with lower survival rate ( 44 , 45 ).…”

Section: Discussionmentioning

confidence: 99%

The Efficacy of Intra-Arterial Plus Intravesical Chemotherapy Versus Intravesical Chemotherapy Alone After Bladder-Sparing Surgery in High-Risk Bladder Cancer: A Systematic Review and Meta-Analysis of Comparative Study

et al. 2021

View full text Add to dashboard Cite

BackgroundDue to the poor prognosis, the treatment of high-risk bladder cancer (HRBC) remains controversial. This meta-analysis aims to access the efficacy of intra-arterial chemotherapy (IAC) combined with intravesical chemotherapy (IC) versus IC alone after bladder-sparing surgery in HRBC.MethodsA systematic search of PubMed, Cochrane Library databases, EMBASE (until June 2020) was conducted. PRISMA checklist was followed. The data were analyzed by RevMan v5.3.0.ResultsA total of five articles including 843 patients were studied. The analysis demonstrated that the IAC + IC group had a greater improvement of overall survival (P = 0.02) and significant reduction in terms of tumor recurrence rate (P = 0.0006) and tumor progression rate (P = 0.008) compared with the IC group. The recurrence-free survival in the IAC + IC group was significantly higher than that in the IC group (P = 0.004), but there was no significant difference in progression-free survival between the two groups (P = 0.32). In addition, the combination of IAC and IC significantly extended tumor recurrence interval (P = 0.0001) and reduced tumor-specific death rate (P = 0.01) for patients with HRBC compared with IC alone. For side effects related with IAC, although about half of the patients experienced some toxicities, most of them were mild and reversible (grades 1–2, 22.3% vs. grade 3–4, 2.7%), mainly including nausea/vomiting (P = 0.0001), neutropenia (P = 0.002), and alanine aminotransferase (P = 0.0001).ConclusionPatients with HRBC treated with IAC + IC after bladder-sparing surgery had a marked improvement in the overall survival, recurrence-free survival, time interval to first recurrence, tumor recurrence rate, tumor progression rate, and tumor-specific death rate than patients treated with IC alone. However, progression-free survival was not significantly correlated with treatment strategy. In addition, patients seemed to tolerate well the toxicities related with IAC. Systematic Review RegistrationPROSPERO, identifier CRD42021232679.

show abstract

“…In recent years, ICIs have become an important therapeutic strategy in many solid tumors [54][55][56][57][58][59]. High levels of PD-L1 expression have been found in mUC with poor outcome.…”

Section: Advanced or Metastatic Bladder Cancer 41 First-line Therapymentioning

confidence: 99%

Immune Checkpoint Inhibitors in Urothelial Bladder Cancer: State of the Art and Future Perspectives

Roviello

Catalano

Santi

et al. 2021

Cancers

View full text Add to dashboard Cite

Bladder cancer (BC) is the most common malignancy of the genitourinary tract, with high morbidity and mortality rates. Until recently, the treatment of locally advanced or metastatic urothelial BC was based on the use of chemotherapy alone. Since 2016, five immune checkpoint inhibitors (ICIs) have been approved by the Food and Drug Administration (FDA) in different settings, i.e., first-line, maintenance and second-line treatment, while several trials are still ongoing in the perioperative context. Lately, pembrolizumab, a programmed death-1 (PD-1) inhibitor, has been approved for Bacillus Calmette–Guérin (BCG)-unresponsive high-risk non-muscle invasive bladder cancer (NMIBC), using immunotherapy at an early stage of the disease. This review investigates the current state and future perspectives of immunotherapy in BC, focusing on the rationale and results of combining immunotherapy with other therapeutic strategies.

show abstract

Immunotherapy and urothelial carcinoma: An overview and future prospectives

Cited by 21 publications

References 57 publications

A new m6A methylation-related gene signature for prognostic value in patient with urothelial carcinoma of the bladder

A new m6A methylation-related gene signature for prognostic value in patient with urothelial carcinoma of the bladder

The Efficacy of Intra-Arterial Plus Intravesical Chemotherapy Versus Intravesical Chemotherapy Alone After Bladder-Sparing Surgery in High-Risk Bladder Cancer: A Systematic Review and Meta-Analysis of Comparative Study

Immune Checkpoint Inhibitors in Urothelial Bladder Cancer: State of the Art and Future Perspectives

Contact Info

Product

Resources

About